Hologic (HOLX) director granted 3,190 RSUs vesting at 2027 meeting

Rhea-AI Filing Summary

Stamoulis Christiana reported acquisition or exercise transactions in this Form 4 filing.

Hologic Inc. director Christiana Stamoulis reported an equity award of 3,190 restricted stock units (RSUs) of common stock. The RSUs were granted at no cash purchase price and will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders.

Each restricted stock unit will be settled in one share of Hologic common stock on a one-for-one basis. After this award, Stamoulis directly holds 50,526 shares of Hologic common stock, reflecting her updated ownership position as reported in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stamoulis Christiana

(Last) (First) (Middle)

250 CAMPUS DRIVE

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		3,190(1)	A	(2)	50,526	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.

2. Restricted stock units are settled in shares of common stock on a one-for-one basis.

	/s/ Mark W. Irving, attorney-in-fact for Ms. Stamoulis	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Hologic (HOLX) director Christiana Stamoulis report?

Christiana Stamoulis reported receiving 3,190 restricted stock units of Hologic common stock as an equity award. The award was reported as a grant or other acquisition, not an open-market purchase, and carries no cash purchase price per share in the filing.

When do Christiana Stamoulis’s new Hologic (HOLX) restricted stock units vest?

The 3,190 restricted stock units granted to Christiana Stamoulis vest on the date of Hologic’s 2027 Annual Meeting of Stockholders. Vesting on the meeting date links the award to her continued board service through that shareholder meeting.

How are the restricted stock units reported by Hologic (HOLX) settled?

The restricted stock units granted to Christiana Stamoulis are settled in Hologic common stock on a one-for-one basis. This means each vested unit converts into one share of common stock, directly aligning the award’s value with the company’s share price.

How many Hologic (HOLX) shares does Christiana Stamoulis hold after this Form 4 transaction?

After the reported grant of 3,190 restricted stock units, Christiana Stamoulis is shown as directly owning 50,526 shares of Hologic common stock. This figure reflects her updated direct ownership position following the equity award disclosed in the Form 4.

Was Christiana Stamoulis’s Hologic (HOLX) transaction a stock purchase or a grant?

The Form 4 identifies the transaction as a grant, award, or other acquisition coded "A," not an open-market stock purchase. The 3,190 restricted stock units were awarded at a reported price of $0.0000 per share, indicating a compensatory equity grant.